Javelin Pharmaceuticals, Inc. hosts a conference call, with CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, discussing the Company's quarterly results for the period ending March 31, 2008.

About Javelin Pharmaceuticals, Inc.:

Javelin is a specialty pharmaceutical company that applies proprietary technologies to develop new drugs and improved formulations of existing drugs for pain management. Specialty pharmaceutical analysts from six investment firms cover Javelin Pharmaceuticals, Inc. Javelin's headquarters are located in Cambridge, Massachusetts with European offices in Cambridge, England and Cologne, Germany. For additional information, visit www.javelinpharmaceuticals.com.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer of specialty pharmaceutical products for pain management, recently reported its unaudited financial results for the first quarter ended March 31, 2008.

Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's quarterly results for the period ending March 31, 2008. The call will be held Wednesday, May 14, 2008 at 8:30 a.m. EDT.

The Company invites all interested parties to participate. The call will be web cast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website www.javelinpharmaceuticals.com.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer and marketer of specialty pharmaceutical products for pain management, has received commitments from selected investors to purchase up to 11,450,000 shares of its common stock at a purchase price of $2.41 per share.

The purpose of the offering is to enhance our balance sheet as we proceed in our ongoing partnership discussions.

Certain officers and directors of Javelin will participate in this offering.

The closing of the offering is expected to take place on May 13, 2008, subject to customary closing conditions. The total number of shares to be sold in the offering are up to 11,450,000 with the gross proceeds of up to $27.6 million. The company estimates that net proceeds from the offering will be approximately $25.7 million, after deducting placement agent fees and estimated offering expenses.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer and marketer of specialty pharmaceutical products for pain management, has appointed John C. Taylor as Vice President, Business Development. Mr. Taylor will report to Javelin’s recently appointed CEO Martin J. Driscoll and will be responsible for daily execution of Javelin’s global partnership initiatives for its late stage product pipeline.

“I have placed a high priority on Business Development initiatives as a strategic element of Javelin’s new commercialization strategy. Our first commercial partnership will be structured to accelerate the market uptake for our brand, reduce our exposure to early commercialization risk, and augment our growth capital while providing future upside. John will play an essential role in assisting us as we complete this effort,” said Martin Driscoll, Chief Executive Officer.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News)— announced today Martin J. Driscoll, Chief Executive Officer, will present at the 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008 at 2:00 p.m. GMT in Ballroom A at the Four Seasons Hotel London, England.

About Javelin Pharmaceuticals, Inc.

Presentation to be webcast live

Javelin Pharmaceuticals, Inc. (Amex: JAV - News) today announced that CEO Martin J. Driscoll will present a corporate overview to investors at the 28th Annual Cowen & Company Health Care conference. Mr. Driscoll’s presentation will take place on Monday, March 17, 2008 at 4:00pm in the Regis Room on the Third Floor at the Boston Marriott Copley Place.

Market Potential for Dyloject Expands in UK

Today Javelin Pharmaceuticals Inc. (AMEX: JAV - News) announced that Dyloject® (diclofenac sodium solution for injection) has been accepted by the Scottish Medicines Consortium (SMC) for use within the National Health Service (NHS) Scotland, for the treatment or prevention of postoperative pain by intravenous injection, in supervised healthcare settings at the NHS Tariff Price of £48 per pack (10 x 75mg/2ml vials).

Javelin Pharmaceuticals, Inc. (Amex: JAV - News) recently reported its audited financial results for the full year and quarter ending December 31, 2007.

Financial Highlights for the Year Ended December 31, 2007:

Javelin Pharmaceuticals, Inc. hosts a conference call, with Dr. Daniel B. Carr, CEO and CMO, and Stephen J. Tulipano, CPA, CFO, discussing the Company's annual results for the period ending December 31, 2007.

About Javelin Pharmaceuticals, Inc.:

Javelin is a specialty pharmaceutical company that applies proprietary technologies to develop new drugs and improved formulations of existing drugs for pain management. Specialty pharmaceutical analysts from six investment firms cover Javelin Pharmaceuticals, Inc. Javelin's headquarters are located in Cambridge, Massachusetts with European offices in Cambridge, England and Cologne, Germany. For additional information, visit www.javelinpharmaceuticals.com.

Dr. Daniel B. Carr Becomes Vice Chairman and will Continue as Chief Medical Officer

Javelin Pharmaceuticals Inc. (AMEX: JAV - News) today announced that its Board of Directors has appointed Javelin Director and veteran pharmaceutical executive Martin J. Driscoll to the position of Chief Executive Officer, effective immediately. Dr. Daniel B. Carr has become Vice Chairman of the Board of Directors and will continue in his role as Chief Medical Officer.

Javelin’s Board of Directors has also established a Strategic Commercialization and Partnership Committee consisting of members with significant experience in creating partnerships and commercial ventures. The Committee will consist of Directors Peter D. Kiernan III, Neil W. Flanzraich, and Georg Nebgen.

Javelin Pharmaceuticals (AMEX: JAV - News) announced today that the Company recently advised the American Stock Exchange (“Amex”) that it has regained compliance with Sections 121A and 802(a) of the Amex Company Guide and is currently in compliance with the Amex Rules regarding director independence.

The deficiency was first reported on February 7, 2008, when Javelin filed a Current Report on SEC Form 8-K stating that the Company no longer complied with Amex Rules regarding director independence. This deficiency resulted from the determination that a company director, Mr. Martin Driscoll, no longer qualified as independent.

On February 18, 2008, Javelin’s Board of Directors elected Mr. Peter D. Kiernan, III, as a director and qualified him as independent under the Amex Rules. At the time of his appointment, the Board had not yet determined the total number of directors who qualified as independent.

Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today it has accepted the resignation of Dr. Curtis Wright, its Executive Vice President for Risk Management and Regulatory Affairs, for personal reasons. Dr. Wright will pursue a business opportunity outside the field of pain drug development that offers him the opportunity to work closer to his home and continue as a consultant to Javelin.

Javelin Pharmaceuticals (AMEX: JAV - News) announced today that it recently completed accrual of subjects in the last of four planned Phase 1 human pharmacokinetic (PK) studies needed to support its intended filing of a New Drug Application (NDA) next year for its intranasal ketamine product candidate, PMI-150.

Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that Dr. Daniel B. Carr, CEO and CMO, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's annual results for the period ending December 31, 2007. The call will be held Thursday, March 6, 2008 at 4:15 p.m. EST.

The Company invites all interested parties to participate. The call will be webcast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website at: www.javelinpharmaceuticals.com.

Former Goldman Sachs Veteran Financial Expert Joins Javelin Board

Javelin Pharmaceuticals Inc. (AMEX: JAV - News) today announced that its Board of Directors recently voted to increase the size of the Board from seven members to eight, and that it has elected Peter D. Kiernan, III, to fill the newly created directorship. Mr. Kiernan was qualified by the Board as an independent director.

Javelin Pharmaceuticals Inc. (AMEX: JAV - News) today announced that it recently received notification that it had been granted a commercially important Canadian patent with broad claims, enabling greater protection of Javelin's PMI-150 (intranasal ketamine). Canadian Patent Number 2,184,007 entitled: “Nasal and Ocular Administration of ketamine to manage Pain and for Detoxification” provides protection covering Javelin's intranasal ketamine drug into 2015.

... Differentiating Dyloject from Ketorolac and Aspirin

Javelin Pharmaceuticals Inc. (AMEX: JAV - News) today will present results of a new Phase I study of Dyloject™ (injectable diclofenac sodium) demonstrating minimal effects upon platelet function at a clinically effective dose. In contrast, aspirin and ketorolac each impaired platelet aggregation significantly. Inhibition of platelet aggregation with Dyloject and another comparator, Cataflam (an oral formulation of diclofenac) was detectable but not clearly outside the normal range, although Cataflam inhibited platelet aggregation slightly more than Dyloject. These findings will be presented by Javelin’s CEO/CMO Dr. Daniel Carr as part of a broader corporate update about Javelin at the 26th Annual JPMorgan Healthcare Conference in San Francisco.

Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PT on Tuesday, January 8, 2008. The conference is being held at the Westin St. Francis Hotel in San Francisco, California.

Daniel B. Carr M.D., Javelin's CEO/CMO, will provide an overview of the company, discuss Javelin's business, as well as recent developments, and outline future opportunities. Javelin's presentation will be webcast live for investors and available for replay for a period of three months following the conference. The presentation can be accessed by logging onto the Investor Relations section at the Company's web site at http://www.javelinpharma.com. Those wishing to hear the presentation live should log on approximately five minutes prior to its start.